EGFR and colorectal cancer: Elevated miR-31-3p levels have also been linked to resistance to anti-EGFR therapies in colorectal cancer, potentially through the regulation of downstream signaling pathways such as RAS/RAF/MEK/ERK, which can bypass EGFR inhibition [22].